AstraZeneca Plc’s Covid-19 antibody cocktail was more than 80% successful at both preventing symptomatic disease and stopping the illness from worsening after six months, demonstrating its ability to provide long-lasting protection.
The medicine reduced the risk of developing symptomatic Covid by 83% in one of the trials, after six months follow-up, the company said Thursday. The other, which was on half-year data from outpatient participants with mild-to-moderate illness, found the cocktail reduced the risk of severe disease or death by 88%.
